Fc-Mimetic Polypeptides for Anti-Inflammatory T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for inflammatory disorders, such as autoimmune diseases, often require high doses of IVIG to achieve anti-inflammatory effects due to the limited population of IgG with terminal α2,6 sialic acid linkages, and there is a need for more effective and less side-effect prone agents.
Innovation Solution
Development of non-sialylated polypeptides, such as the F241A variant, which mimic the structural and functional properties of sialylated IgG Fc, allowing for enhanced anti-inflammatory activity by binding to type II Fc receptors and inducing IL-33 production, thereby activating regulatory T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of IVIG are administered to enrich sialylated IgGs, then anti-inflammatory activity is improved, but side effects increase and treatment complexity increases
Solution Approach 1:
The invention extracts and isolates the specific anti-inflammatory mechanism by focusing on sialylated IgG subclasses (particularly IgG1 and IgG3 with terminal sialic acid) from the complex IVIG mixture. This allows for targeted therapeutic action using only the beneficial sialylated components, avoiding the side effects associated with high-dose IVIG administration of non-sialylated IgG subclasses.
Solution Approach 2:
The invention applies local quality by creating IgG variants with specific localized modifications - namely, controlled sialylation at particular glycosylation sites (Asn297) while maintaining the overall IgG structure. This localized modification approach enables anti-inflammatory activity without requiring high doses of fully sialylated IVIG, thereby reducing side effects.
2Reliability
If high doses of IVIG are administered to enrich sialylated IgGs, then anti-inflammatory activity is improved, but treatment cost and complexity increase
Solution Approach 1:
The invention creates simplified copies or variants of sialylated IgG with defined sequences (such as those with specific glycosylation patterns at Asn297) that replicate the anti-inflammatory function. These engineered variants provide consistent, predictable activity without the variability and complexity of high-dose IVIG enrichment protocols.
3Reliability
If sialylated IgG is used for anti-inflammatory treatment, then regulatory T cell activation is improved, but the limited population of sialylated IgG in IVIG reduces effectiveness
Solution Approach 1:
The invention changes the key parameter of sialylation status by engineering IgG variants with controlled sialylation at specific glycosylation sites. This parameter change ensures high concentrations of functionally active sialylated IgG without relying on the limited natural occurrence in standard IVIG preparations, thereby improving regulatory T cell activation consistency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The F241A variant demonstrates potent anti-inflammatory effects in both antibody- and T cell-mediated autoimmune models, reducing the need for high-dose IVIG and minimizing side effects.
Implementation Method 1
the polypeptide has ability to bind to DC-SIGN, and to bind to hFcγRIIA or RIIB
Implementation Method 2
inducing IL-33 production, thereby activating regulatory T cells
Data Source
AI summary
This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.